Drugs / Lactoferrin Bovine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT05283278 Comparator | Feb 2020 → Mar 2021 | fungal infectious disease | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT06072521 Comparator | Oct 2023 → Sep 2024 | hepatic encephalopathy | Al-Azhar University | Unknown | No outcome recorded |
| Phase 4 | NCT04445948 Comparator | Nov 2019 → Jun 2020 | Helicobacter pylori infectious disease | Alexandria University | Completed | No outcome recorded |
| Phase 4 | NCT04267653 Comparator | Jan 2018 | iron deficiency anemia | Assiut University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactoferrin Bovine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04445948 ↗ |
| Modality | Protein / enzyme biologic | “Lactoferrin (Lf) is a mammalian cationic iron binding glycoprotein belonging to the transferrin family” NCT04267653 ↗ |
| Route | Oral | “Oral bovine lactoferrin (bfl) 100 mg once daily on empty stomach” NCT04267653 ↗ |